Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

SDCL ends sale process as subsidiary Onyx secures new facility

(Sharecast News) - SDCL Efficiency Income Trust said in an update on Wednesday that its US subsidiary Onyx Renewable Partners has secured a new $260m senior secured credit facility to support the expansion of its distributed energy portfolio. The London-listed firm said the new facility, arranged by Apterra Infrastructure Capital, replaced an existing $115m revolving credit facility, and would fund ongoing solar photovoltaic and battery storage projects across the United States.

It described the financing as a milestone in Onyx's development, enabling the platform to self-fund its near-term pipeline and reducing SDCL's own future funding commitments from its revolving facility.

The company noted that it would have minimal impact on overall portfolio gearing.

While the majority of Onyx's valuation was based on contracted assets, up to 15% related to platform value tied to its growth prospects - an element more difficult to monetise in the current US market environment, which SDCL described as hampered by policy uncertainty.

Although the company received multiple offers for a full disposal of Onyx, SDCL said they did not meet acceptable terms.

It said it had now ended the formal sale process, and was instead exploring privately negotiated alternatives, including equity partnerships tied to Onyx's contracted portfolio.

A select group of counterparties had been invited into discussions, with further updates to be provided in the company's upcoming annual report.

At 1035 BST, shares in SDCL Efficiency Income Trust were up 2.94% at 49p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.